InvestorsHub Logo
Followers 30
Posts 1939
Boards Moderated 0
Alias Born 01/11/2011

Re: senderos post# 174168

Tuesday, 12/01/2015 1:28:02 PM

Tuesday, December 01, 2015 1:28:02 PM

Post# of 403253
Did a quick Google...

On Monday, Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), gained 11.16% to $2.39.

Eisai Inc. and Arena Pharmaceuticals, declared that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended release formulation of lorcaserin. If approved, the extended release formulation will offer patients a chronic weight administration treatment in a once-daily dosing option.

http://www.wsnewspublishers.com/notable-stocks-in-the-spotlight-arena-pharmaceuticals-inc-nasdaqarna-chicos-fas-inc-nysechs-paychex-inc-nasdaqpayx/1542206/

-----------------------------------------------

This stock spiked 40% on day of announcement.

Lightlake Therapeutics Inc. Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NDA and Grants Priority Review Status - See more at:

http://globenewswire.com/news-release/2015/09/25/771050/10150583/en/Lightlake-Therapeutics-Inc-Announces-FDA-Accepts-for-Review-Adapt-Pharma-Limited-s-NARCAN-R-Naloxone-Hydrochloride-Nasal-Spray-NDA-and-Grants-Priority-Review-Status.html#sthash.cF8QPTos.dpuf






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News